Увійти

Готові списки джерел за темами / Alfuzosine / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Alfuzosine.

Статті в журналах з теми "Alfuzosine"

Автор: Grafiati

Опубліковано: 28 жовтня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Alfuzosine".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Marini, F., F. Martino, V. Alfano, G. P. Vancini, and R. Valente. "Trattamento Sintomatico Dell'Ipertrofia Prostatica Benigna Con Alfuzosine." Urologia Journal 57, no. 1 (February 1990): 29–34. http://dx.doi.org/10.1177/039156039005700105.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Guerre, A., D. M. Hartl, and P. Katz. "Les Alpha-1-Bloquants (alfuzosine) en pathologie salivaire obstructive." Revue de Stomatologie et de Chirurgie Maxillo-faciale 111, no. 3 (June 2010): 135–39. http://dx.doi.org/10.1016/j.stomax.2010.04.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

de Goede, A. "Alfuzosine geeft geen vermindering van symptomen van chronische prostatitis-chronische bekkenpijnsyndroom." Medisch-Farmaceutische Mededelingen 47, no. 4 (April 2009): 50–51. http://dx.doi.org/10.1007/bf03079915.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Carbin, B. E., P. Bauer, M. Friskand та D. Moyse. "EFFICACY OF ALFUZOSINE (an α₁-adrenoreceptor blocking drug) IN BENIGN HYPERPLASIA OF THE PROSTATE". Scandinavian Journal of Urology and Nephrology 25, sup138 (1 січня 1991): 73–75. http://dx.doi.org/10.1080/21681805.1991.12068870.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

El, Sheikh, Nahla Esmail, Ayman Gouda та Walid Basset. "Extractive spectrophotometric determination of some α-adrenergic-antagonists in pure forms and in pharmaceutical formulations". Chemical Industry and Chemical Engineering Quarterly 18, № 2 (2012): 179–91. http://dx.doi.org/10.2298/ciceq110917060e.

Повний текст джерела

Анотація:

A simple, rapid, and extractive spectrophotometric methods was developed for the determination of some postsynaptic ?-1 adrenoreceptor antagonist; doxazosin mesylate (DOX), terazosin (TRZ) and alfuzosine HCl (ALF) in pure forms and pharmaceutical formulations. The developed methods are based on the formation of yellow colored chloroform ion-pair complexes between the basic nitrogen of the drugs and dyes, namely; bromocresol green (BCG), bromothymol blue (BTB), methyl orange (MO) and alizarine red S (ARS), in acidic buffer of pH range (3.0-5.0). The formed complexes were extracted with chloroform or dichloromethane and measured at 418, 414, 425 and 426 nm for DOX and at 419, 415, 425 and 428 for TRZ and at 418, 412, 421 and 427 nm for ALF using BCG, BTB, MO and ARS, respectively. The analytical parameters and their effects on the reported systems are investigated. Beer?s law was obeyed in the range 1.0-130 ?g mL?1 with correlation coefficient (n = 6) ? 0.9991. The molar absorpitivity, Sandell sensitivity, detection and quantification limits were also calculated. The composition of the ion associates was found 1:1 by Job?s method. The proposed methods have been applied successfully for the analysis of the studied drugs in pure forms and in pharmaceutical formulations with percentage recoveries ranges from 99.18-100.61. The results of analysis were validated statistically. The results were in good agreement and compared with those obtained with reported methods.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Mari, Andrea, Alessandro Antonelli, Luca Cindolo, Ferdinando Fusco, Andrea Minervini, and Cosimo De Nunzio. "Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis." Therapeutic Advances in Urology 13 (January 2021): 175628722199328. http://dx.doi.org/10.1177/1756287221993283.

Повний текст джерела

Анотація:

Background: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are a bothersome frequent symptom in adult males. This systematic review analyzed the available evidence on the pharmacokinetic and pharmacodynamic features of alfuzosin, and its clinical efficacy both as monotherapy and in combination with other drugs for the treatment of male LUTS/BPH. Methods: A systematic review of the last 10 years was performed using the MEDLINE, EMBASE and Cochrane libraries in March 2020. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42020136120) and is available in full on the University of York website. Results: Alfuzosin is a quinazoline derivative and, although a nonspecific α1-blocker, exhibits a selective concentration in the prostate compared with plasma in patients with BPH. Three registration trials assessed the safety and efficacy of alfuzosin. The 10 mg daily formulation has a three-layered matrix containing the active substance between two inactive coats allowing a drug release over 20 h. Alfuzosin showed high tolerability, few vasodilatory effects and a low rate of ejaculation disorders over older alpha-blocking compounds thanks to the high uroselectivity of alfuzosin and its preferential concentration at urinary level. Six randomized clinical trials (RCTs) assessed efficacy and safety of alfuzosin versus other alpha-blockers ± placebo: three studies comparing with tamsulosin, one with doxazosin, and two with silodosin or tamsulosin. One RCT investigated the clinical outcomes of alfuzosin with finasteride, two with propiverine and two with phosphodiesterase-5 inhibitors. Conclusions: Alfuzosin is an effective drug for the treatment of LUTS/BPH, with a lower rate of sexual disorders compared with other alpha-blockers. Alfuzosin is also safe with low adverse events in case of concomitant antihypertensive therapy and in patients with cardiovascular morbidity. Safety and efficacy of alfuzosin has been reported also in case of combination therapy with antimuscarinic agents and PDE5i.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Siddique, Md Saifuddin Ahmed, Sharmin Nahar Bashar, Mohammed Monowar UL Haque, Md Abdul Latif, and Farid Uddin Ahmed. "Comparison Between Alfuzosin Monotherapy And Combination of Alfuzosin With Finasteride In Symptomatic Benign Prostatic Hyperplasia." Journal of Chittagong Medical College Teachers' Association 28, no. 2 (February 10, 2018): 75–80. http://dx.doi.org/10.3329/jcmcta.v28i2.62426.

Повний текст джерела

Анотація:

Background: Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) are common in elder men and a number of drugs alone or combined are clinically used for this disorder. This study was aimed to evaluate the efficacy and safety of Alfuzosin monotherapy versus combination of Alfuzosin and Finasteride in treatment of LUTS due to BPH. Materials and methods: This clinical trial was conducted in the outpatient Department of Urology Chittagong Medical College Hospital from May 2007 to October 2008. After assessing for the eligibility, consecutive consenting 60 patients with LUTS related to BPH were randomly assigned to either 10mg Alfuzosin (Group A) or combination of 10mg Alfuzosin and 5mg Finasteride (Group B) for 12 months. The response was assessed by measurements of International Prostate Symptoms Score (IPSS) Maximum urine flow rate (Qmax), Post Voidal Residual Volume (PVR) and prostate volume at baseline and 3 monthly thereafter. Safety was assessed by Adverse Drug Events (ADE) rate. Results: Both Groups showed comparable significant improvements in all parameters in terms of decreasing IPSS, PVR and increasing Qmax. Both treatments were well tolerated with respect to ADE and distribution of ADE was similar in two groups. Conclusion: In men with benign prostatic hyperplasia, Alfuzosin was effective therapy and the combination of Alfuzosin and Finasteride was no more effective than Alfuzosin alone. JCMCTA 2017 ; 28 (2) : 75-80

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Vamsi Krishna, M., and D. Gowri Sankar. "Optimization and Validation of Quantitative Spectrophotometric Methods for the Determination of Alfuzosin in Pharmaceutical Formulations." E-Journal of Chemistry 4, no. 3 (2007): 397–407. http://dx.doi.org/10.1155/2007/912762.

Повний текст джерела

Анотація:

Three accurate, simple and precise spectrophotometric methods for the determination of alfuzosin hydrochloride in bulk drugs and tablets are developed. The first method is based on the reaction of alfuzosin with ninhydrin reagent inN, N'-dimethylformamide medium (DMF) producing a colored product which absorbs maximally at 575 nm. Beer’s law is obeyed in the concentration range 12.5-62.5 µg/mL of alfuzosin. The second method is based on the reaction of drug with ascorbic acid in DMF medium resulting in the formation of a colored product, which absorbs maximally at 530 nm. Beer’s law is obeyed in the concentration 10-50 µg/mL of alfuzosin. The third method is based on the reaction of alfuzosin withp-benzoquinone (PBQ) to form a colored product with λmax at 400 nm. The products of the reaction were stable for 2 h at room temperature. The optimum experimental parameters for the reactions have been studied. The validity of the described procedures was assessed. Statistical analysis of the results has been carried out revealing high accuracy and good precision. The proposed methods could be used for the determination of alfuzosin in pharmaceutical formulations. The procedures were rapid, simple and suitable for quality control application.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Shrestha, Santosh, DB Adhikari, A. Gurung, S. Pradhan, NV Gurung, A. Acharya, D. Shrestha, et al. "Role of Alfuzosin in Ureteral Stent Related Urinary Symptoms Score: A Comparative Study." Journal of Gandaki Medical College-Nepal 10, no. 1 (August 1, 2017): 28–30. http://dx.doi.org/10.3126/jgmcn.v10i1.17912.

Повний текст джерела

Анотація:

Background: Ureteral stent placement is a routine urological procedure. However, patients inserted with ureteral stent exhibited increased urinary symptoms that compromise patients’ quality of life.Objective: To assess the efficacy of alpha blockers (Alfuzosin) in the management of ureteral stent related urinary symptoms.Methods: Total of 60 patients after ureteral stent insertion was randomly divided into two equal groups; 30 in alfuzosin group and the remaining 30 in control group. Urinary symptoms questionnaire was filled after two weeks and results were statistically analyzed.Results: Urinary symptoms like urgency, frequency and flank pain were significantly less in the alfuzosin group when compared with control group.Conclusion: Alpha blocker (Alfuzosin) was found to be effective in reducing ureteral stent related urinary symptoms.Journal of Gandaki Medical CollegeVol. 10, No. 1, 2017, page: 28-30

Стилі APA, Harvard, Vancouver, ISO та ін.

10

&NA;. "Alfuzosin." Reactions Weekly &NA;, no. 729 (November 1998): 6. http://dx.doi.org/10.2165/00128415-199807290-00015.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

&NA;. "Alfuzosin." Reactions Weekly &NA;, no. 1129 (November 2006): 4. http://dx.doi.org/10.2165/00128415-200611290-00010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

&NA;. "Alfuzosin." Reactions Weekly &NA;, no. 1136 (January 2007): 6. http://dx.doi.org/10.2165/00128415-200711360-00013.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

&NA;. "Alfuzosin." Reactions Weekly &NA;, no. 1355 (June 2011): 7. http://dx.doi.org/10.2165/00128415-201113550-00021.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Wilde, Michelle I., Andrew Fitton, and Donna McTavish. "Alfuzosin." Drugs 45, no. 3 (March 1993): 410–29. http://dx.doi.org/10.2165/00003495-199345030-00008.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

&NA;. "Alfuzosin." Reactions Weekly &NA;, no. 1096 (April 2006): 4. http://dx.doi.org/10.2165/00128415-200610960-00013.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

&NA;. "Alfuzosin." Reactions Weekly &NA;, no. 1114 (August 2006): 6. http://dx.doi.org/10.2165/00128415-200611140-00014.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

McKeage, Kate, and Greg L. Plosker. "Alfuzosin." Drugs 62, no. 4 (2002): 633–53. http://dx.doi.org/10.2165/00003495-200262040-00009.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

&NA;. "Alfuzosin." Reactions Weekly &NA;, no. 1023 (October 2004): 6. http://dx.doi.org/10.2165/00128415-200410230-00017.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

&NA;. "Alfuzosin." Reactions Weekly &NA;, no. 1344 (March 2011): 6. http://dx.doi.org/10.2165/00128415-201113440-00011.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Das, Supratik, Harjinder Singh, Vijay Kumar, and Jasbir Singh. "A comparative study of efficacy of tadalafil and alfuzosin regimens in patients of benign prostate hyperplasia." International Journal of Basic & Clinical Pharmacology 7, no. 6 (May 22, 2018): 1123. http://dx.doi.org/10.18203/2319-2003.ijbcp20182093.

Повний текст джерела

Анотація:

Background: Aim of the study was to compare efficacy of Tadalafil and Alfuzosin regimens in patients of Benign Prostate Hyperplasia.Methods: It was a comparative, prospective, observational, non-invasive, parallel and randomised study conducted at the Outpatient Department of Urology, Rajindra Hospital, Patiala. 60 patients diagnosed with Benign Prostate Hyperplasia along with Lower Urinary Tract Symptoms, out which, 30 patients, consuming Tadalafil and 30 patients consuming Alfuzosin were considered. History regarding the concerned disease and the compliance of treatment was taken. Symptom scores were assessed with the help of International Prostate Symptom Score, Quality of Lifestyle Score and Erectile Dysfunction Score. Physical examination consisting of Focused Neurological Examination along with Digital Rectal Examination were conducted. Parameters like Renal Function Test, Urine analysis, Ultrasound of Prostate and uroflowmetry were also considered.Results: The mean age selected for study was 64 years for Tadalafil and Alfuzosin group. The mean level of IPS Score, Qol Score and ED Score at the first day of inclusion of patients were 23.96±4.49, 4±0.78, and 25.33±4.02 respectively for Tadalafil group and regarding Alfuzosin group they were 25.23±4.84, 3.56±0.81, and 26.1±4.04 respectively. Follow ups were conducted at 15 days, 1 month and 3 months for both the groups which were found to be statistically significant after 3 months and Alfuzosin showed a favourable result.Conclusions: Alfuzosin 10mg given at daily dose was found to have higher efficacy than Tadalafil (5mg).

Стилі APA, Harvard, Vancouver, ISO та ін.

21

&NA;. "Alfuzosin/tamsulosin." Reactions Weekly &NA;, no. 1265 (August 2009): 6. http://dx.doi.org/10.2165/00128415-200912650-00015.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Borg, F., J. L. Cazor, and M. Dimsdale. "Alfuzosin hydrochloride." Drugs of the Future 11, no. 10 (1986): 821. http://dx.doi.org/10.1358/dof.1986.011.10.61928.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Karadeniz, A., İ. Pişkin, D. Eşsiz, and L. Altintaş. "Relaxation Responses of Trigonal Smooth Muscle from Rabbit by Alpha1-Adrenoceptor Antagonists Alfuzosin, Doxazosin and Tamsulosin." Acta Veterinaria Brno 77, no. 1 (2008): 81–88. http://dx.doi.org/10.2754/avb200877010081.

Повний текст джерела

Анотація:

This study was performed to investigate the effects of alfuzosin, doxazosin and tamsulosin in vitro on trigone smooth muscle of rabbit. In this study, fifteen rabbits weighing 2.5 - 3 kg were used. One strip in the shape of a trigone was prepared for each of the isolated bladders. Firstly, an initial tension of 1 g was placed on each segment, and we waited for equilibration by constantly bubbling with 95% O2 and 5% CO2. Next, the determination level of electrical stimulation which created submaximal contraction and effective dosage were found for trigone and they were determined by applying different concentrations of phenylephrine (10-8 M, 10-7 M, 10-6 M, 10-5 M), respectively. Firstly 10-8 M dosage of alfuzosin (10-8 M, 10-7 M, 10-6 M, 10-5 M) was added, then we waited for 20 min. Then, an effective dosage of phenylephrine (10-5 M) was added into the solution and we waited for 7 min again. After this process, electrical stimulation was applied for the contraction of the tissue. After stimulation, the tissue was washed twice every two minutes and rested; we waited until the tissue reached its starting stretching value. The same processes were performed for the other dosages of alfuzosin (10-7 M, 10-6 M, 10-5 M), doxazosin (10-7 M, 10-6 M, 10-5 M) and tamsulosin (10-7 M, 10-6 M, 10-5 M), respectively. In conclusion, when we compared the amplitudes of the responses of all concentrations of doxazosin, alfuzosin and tamsulosin in the trigone smooth muscle with amplitude of a response of effective concentration of phenylephrine, it was determined that the prevention level of contractions occurred after tamsulosin hydrochloride was higher than after alfuzosin hydrochloride and doxazosin mesylate. With these results, we showed that alfuzosin, doxazosin and tamsulosin inhibited noradrenalin-based contractions in the rabbit trigone smooth muscle and this result can be used both for in vitro and in vivo future studies.

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Sentürk, Aykut Buğra, Cemil Aydin, Musa Ekici, Muhammet Yaytokgil, Ali Akkoc, and Mehmet Murat Baykam. "Comparison of three most frequently used alpha blocker agents in medical expulsive therapy for distal ureteral calculi, result of a retrospective observational study." Archivio Italiano di Urologia e Andrologia 90, no. 1 (March 31, 2018): 25. http://dx.doi.org/10.4081/aiua.2018.1.25.

Повний текст джерела

Анотація:

Purpose: In this study, we compared the effects of three agents frequently used in daily life for medical expulsive therapy. Materials and methods: A total of 143 patients meeting the criteria were included in the study. Patients were divided into three homogeneous drug groups which were tamsulosin group (n:48), alfuzosin group (n:47) and silodosin group (n:48). The time of stone expulsion, analgesic needs, side effects of the medicine and endoscopic intervention needs of the patients were recorded. Results: The rate of stone expulsion was 70.8% (n:34) in tamsulosin group, 70.2% (n:33) in alfuzosin group, and 75% (n:36) in silodosin group. No significant difference was observed among the rates of stone expulsion in three groups, and the rates of stone expulsion were similar (p = 0.778). The duration of stone expulsion was significantly different in the groups (p = 0.012): the time of stone expulsion for tamsulosin was 2.33 ± 0.78 days longer than for Silodosin, indicating a significant difference. There was no significant difference between tamsulosin-alfuzosin and silodosin-alfuzosin (respectively p = 0.147, p = 0.925). Conclusions: The results of this study showed that medical expulsive therapy by using alpha blocker agents is safe and efficacious. This option must be kept in mind for patients who do not ask for surgery as the first-step treatment for eligible patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Lapitan, MCM, V. Acepcion, and J. Mangubat. "A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Trial." Journal of International Medical Research 33, no. 5 (September 2005): 562–73. http://dx.doi.org/10.1177/147323000503300512.

Повний текст джерела

Анотація:

This randomized, double-blind, parallel-design trial compared the efficacy and safety of tamsulosin and alfuzosin in 76 men with symptomatic benign prostatic hyperplasia. Patients were randomized to receive 0.2 mg tamsulosin once daily orally ( n = 40) or 10 mg alfuzosin once daily orally ( n = 36), and changes in the International Prostate Symptom Score (IPSS), maximal urinary flow rate (Qmax) and the Danish prostatic symptom sexual function score and morbidity rates were compared after 8 weeks of treatment. There was a mean overall decrease in the IPSS, with no significant difference between the treatment groups. There was an overall increase in the Qmax, which again was similar in the two groups. There was no significant change in the sexual function scores in either group. The incidence of adverse events was similar for tamsulosin (25%) and alfuzosin (19.4%) therapy. In conclusion, both treatment regimens similarly improved the IPSS and Qmax, did not alter sexual function and were well tolerated.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Piya, B., SK Singh, and R. Gurung. "Tamsulosin versus Alfuzosin as medical therapy for ureteric stones." Journal of Society of Surgeons of Nepal 18, no. 3 (July 25, 2016): 37. http://dx.doi.org/10.3126/jssn.v18i3.15300.

Повний текст джерела

Анотація:

Objectives: To evaluate and compare the efficacy of tamsulosin and alfuzosin as medical therapy in ureteric stones.Patients and Methods: A total of 87 patients with ureteral stones of size ≤10 mm were randomly divided into 3 groups. Group I patients (n-30) received 0.4 mg of tamsulosin daily, group II patients (n-29) received 10 mg of alfuzosin daily and group III patients (n-28) received no alpha blockers. All patients were given analgesia when needed. Follow up was done in weekly basis for 4 weeks.Results: The mean stone size (5.33±1.58, 5.79±1.84, 5.67±1.64) and age (29.1±6.3, 30.31±7.22, 29.4±7.63) were comparable in each groups. The stone expulsion rate was 83.3%, 79.3% and 50% in group I, II and III respectively. The drugs related side effects reported by patients were mild and transient.Conclusion: The use of tamsulosin and alfuzosin for the medical treatment of ureteric stones proved to be safe and effective and neither did have any significant benefits over the other

Стилі APA, Harvard, Vancouver, ISO та ін.

27

&NA;. "Alfuzosin/antipsychotics/galantamine." Reactions Weekly &NA;, no. 1418 (September 2012): 7–8. http://dx.doi.org/10.2165/00128415-201214180-00028.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Zabala, S., C. Thomson, S. Valdearcos, A. Gascon, and M. A. Pina. "Alfuzosin-induced hepatotoxicity." Journal of Clinical Pharmacy and Therapeutics 25, no. 1 (January 2000): 73–74. http://dx.doi.org/10.1046/j.1365-2710.2000.00259.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

&NA;. "Alfuzosin study criticised." Inpharma Weekly &NA;, no. 798 (August 1991): 3. http://dx.doi.org/10.2165/00128413-199107980-00005.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Vela-Casasempere, P. "Alfuzosin-associated dermatomyositis." Rheumatology 37, no. 10 (October 1, 1998): 1135–36. http://dx.doi.org/10.1093/rheumatology/37.10.1135.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Rawat, Karuna A., Hirakendu Basu, Rakesh Kumar Singhal, and Suresh Kumar Kailasa. "Simultaneous colorimetric detection of four drugs in their pharmaceutical formulations using unmodified gold nanoparticles as a probe." RSC Advances 5, no. 26 (2015): 19924–32. http://dx.doi.org/10.1039/c4ra16109b.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Karakose, Ayhan, Ozgu Aydogdu, and Yusuf Ziya Atesci. "The relationship between bladder wall thickness and lower urinary tract symptoms: Does bladder wall thickness change after alpha-blocker therapy with alfuzosin?" Canadian Urological Association Journal 8, no. 1-2 (January 14, 2014): 26. http://dx.doi.org/10.5489/cuaj.1513.

Повний текст джерела

Анотація:

Introduction: We evaluate the association between lower urinary tract symptoms (LUTS) and bladder wall thickness (BWT) and investigate whether alfuzosin might improve BWT.Methods: We retrospectively reviewed the data of 164 patients with LUTS. Patients were divided into 2 groups according to BWT(Group 1: BWT ≤5 mm, n = 69; Group 2: BWT >5 mm, n = 95). Age, international prostate symptom score (IPSS), maximum and average urinary flow rates (Qmax and Qave), quality of life (QoL), postvoid residual (PVR) urine volume, prostate volume and prostate-specific antigen (PSA) were compared between the 2 groups. In total, 102 patients underwent transurethral resection of the prostate (TURP) and 62 patients were treated with alfuzosin. We compared BWT, Qmax, Qave, IPSS, QoL, PVR and PSA before and at the sixth month of alfuzosin therapy. A p value of <0.05 was considered statistically significant.Results: The mean BWT of Group 1 was 3.72 ± 0.56 mm and Group 2 was 6.43 ± 1.13 mm. There was a significant difference between the 2 groups in terms of mean Qmax and PVR. There was no statistical difference between the groups in terms of Qave, IPSS, QoL, prostate volume and PSA. There was significant difference between BWT before (6.8 ± 2.1) and after (4.6 ± 1.3) treatment with alfuzosin in 62 patients (p = 0.02). There was a significant difference between pre- and post-treatment values of mean Qmax, Qave, IPSS, QoL score, and PVR with alfuzosin.Conclusion: BWT is a non-invasive and effective test to evaluate patients with lower urinary tract obstruction and may be used for showing the effectiveness of alpha-blocker therapy in patients with LUTS.

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Tantawy, Mahmoud A., Soheir A. Weshahy, Mina Wadie, and Mamdouh R. Rezk. "A novel HPLC-DAD method for simultaneous determination of alfuzosin and solifenacin along with their official impurities induced via a stress stability study; investigation of their degradation kinetics." Analytical Methods 12, no. 26 (2020): 3368–75. http://dx.doi.org/10.1039/d0ay00822b.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Siddique, Md Saifuddin Ahmed, Sharmin Nahar Bashar, and Farid Uddin Ahmed. "Efficacy and Safety of Combine Alfuzosin and Finasteride in the Treatment of Symptomatic Benign Prostatic Hyperplasia: A Quasi-Experimental Study." Chattagram Maa-O-Shishu Hospital Medical College Journal 16, no. 2 (July 3, 2018): 35–39. http://dx.doi.org/10.3329/cmoshmcj.v16i2.37291.

Повний текст джерела

Анотація:

Background: Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) are common in elder men and a number of drugs alone or in combination are clinically used for this disorder. To assess the efficacy and safety of combined Alfuzosin plus Finasteride, in patients with LUTS due to BHP.Methods: In this hospital-based, Quasi-experimental study (One-Group Pre test-Post test Design) without Control Groups, 30 consecutive patients were selected as per set criteria for medical management of BPH with combination of 10mg Alfuzosin and 5mg Finasteride, for 12-months, in the outpatient Department of Urology, in Chittagong Medical College Hospital. The primary efficacy criteria were improvement in symptoms (International Prostate Symptom Score (IPSS) peak urinary flow rate and reduction of prostate volume from baseline.Results: Combination therapy with Alfuzosin plus Finasteride was effective in improving the symptoms and peak urinary flow rate from the first follow-up visit (Day 90) in comparison to baseline score. The mean change in the IPSS from baseline at endpoint was 10±1.87 (p=0.001). The percentage increase in the peak urinary flow rate was 4.8 mL/s, compared with 11.0±1.82 mL/s at baseline (p=0.001). The patients’ quality of life also significantly improved. The percentage decrease in prostate volume at end point was 15.13±11.3 cc (p=0.001). Overall, this combination therapy was well tolerated. The incidence of orthostatic hypotension as determined by systematic blood pressure measurements was only 3(10%). No clinically relevant ejaculation disorders were observed.Conclusion: Alfuzosin plus Finasteride provides effective relief from the symptoms of benign prostatic hyperplasia by reducing the size of the prostate. It is well tolerated from a cardiovascular viewpoint and is not associated with abnormal ejaculation.Chatt Maa Shi Hosp Med Coll J; Vol.16 (2); July 2017; Page 35-39

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Piya, Bimochan, and Abhishek Bhattarai. "Efficacy of Tamsulosin and Alfuzosin in Management of Distal Ureteral Stones." Med Phoenix 6, no. 1 (July 19, 2021): 10–13. http://dx.doi.org/10.3126/medphoenix.v6i1.36352.

Повний текст джерела

Анотація:

Introduction: Urinary tract calculi are the most frequent condition in urology clinics worldwide. The overall prevalence is about 5 % and lower urinary tract stones account for 70% among them. Medical expulsive therapy has been used to treat distal ureteric stone as it reduces symptoms and facilitates stone expulsion. The aim of this study is to evaluate and compare the efficacy of tamsulosin and alfuzosin as medical therapy in ureteric stones. Materials and Methods: A total of 87 patients with distal ureteral stones of size ≤10 mm were randomly divided into 3 groups. Group A patients (n-30) received 0.4 mg of tamsulosin daily, group B patients (n-29) received 10 mg of alfuzosin daily and group C patients (n-28) received 75 mg of diclofenac sodium. Patients in all groups received diclofenac sodium for one week and then as required. Follow-up was done on a weekly basis for 4 weeks. The stone expulsion rate, time for stone expulsion, and side-effects were recorded in each group. Results: The mean stone size (5.66, 5.79, 5.67) mm and age (29.1, 30.31, 29.4) were comparable in each group. The stone expulsion rate was 83.3%, 79.3%, and 50% in groups A, B, and C respectively. It showed that both the study groups (Group A and Group B) were effective than the control group (p-value 0.006 and 0.02 respectively) but there was no difference between tamsulosin and alfuzosin (p-value 0.69). The duration of stone expulsion was 11.5 days, 11.8 days, and 17.3 days for Group A, B, and C respectively. The drugs related side effects reported by patients were mild and transient. Conclusion: The use of tamsulosin and alfuzosin for the medical treatment of ureteric stones proved to be safe and effective and neither did have any significant benefits over the other.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Wadie, Mina, Ezzat M. Abdel-Moety, Mamdouh R. Rezk, and Hoda M. Marzouk. "A novel smartphone HPTLC assaying platform versus traditional densitometric method for simultaneous quantification of alfuzosin and solifenacin in their dosage forms as well as monitoring content uniformity and drug residues on the manufacturing equipment." RSC Advances 13, no. 17 (2023): 11642–51. http://dx.doi.org/10.1039/d3ra01211e.

Повний текст джерела

Анотація:

A comprehensive comparative study between smartphone image analysis and benchtop densitometric detection for simultaneous HPTLC quantification of alfuzosin and solifenacin with versatile real applications.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Zhao, Yan, Xue-Bin Cao, and Lei-Ming Ren. "Doxazosin selectively potentiates contraction to serotonin via 5-HT2A receptors in longitudinal muscle strips of the rabbit gastric body." Canadian Journal of Physiology and Pharmacology 92, no. 3 (March 2014): 197–204. http://dx.doi.org/10.1139/cjpp-2013-0067.

Повний текст джерела

Анотація:

The aims of this study were to examine the effects of doxazosin on contractile responses to 5-hydroxytryptamine (5-HT), carbachol, and histamine, and to compare them with those of prazosin, alfuzosin, and terazosin, and then characterize a pharmacological profile of the 5-HT-induced contractile response using preparations of isolated longitudinal muscle strips from the rabbit gastric body. The results from these preparations showed that the contraction response to 5-HT, but not to carbachol or histamine, was found to be dose-dependently potentiated by doxazosin and its enantiomers. The specific potentiation effect on 5-HT was not observed in the preparations that were treated with prazosin, terazosin, or alfuzosin. The contractile response to 5-HT and its potentiation by doxazosin were not affected by treatment with phenoxybenzamine. However, 5-HT-induced contraction was competitively antagonized by nefazodone (with pA2 value of 8.64 ± 0.17), and was almost completely inhibited by treatment with indomethacin. In conclusion, doxazosin, but not prazosin, alfuzosin, or terazosin, selectively potentiates 5-HT-induced contraction in the rabbit gastric body strips via an α1-adrenoceptor-independent mechanism, without chiral recognition of its enantiomers. Additionally, the contraction to 5-HT was found to be mediated via 5-HT2A receptors, and was similar to PGs synthesis in the preparations.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Attia, Khalid A. M., Nasr M. El-Abasawi, and Ahmed H. Abdelazim. "Colorimetric estimation of alfuzosin hydrochloride in pharmaceutical preparation based on computational studies." Anal. Methods 8, no. 8 (2016): 1798–805. http://dx.doi.org/10.1039/c5ay02635k.

Повний текст джерела

Анотація:

Computational and theoretical studies were done electronically and geometrically to find a suitable, selective and sensitive coupling agent applicable for diazocoupling estimation of alfuzosin hydrochloride (ALF).

Стилі APA, Harvard, Vancouver, ISO та ін.

39

&NA;. "Alfuzosin/vitamin k2 interaction." Reactions Weekly &NA;, no. 1427 (November 2012): 5–6. http://dx.doi.org/10.2165/00128415-201214270-00012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Farley, Suzanne J. "Alfuzosin improves sexual function." Nature Reviews Urology 6, no. 4 (April 2009): 180. http://dx.doi.org/10.1038/nrurol.2009.36.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Zucconelli, R., P. Belmonte, and G. L. Pappagallo. "Medical Therapy of Benign Prostatic Hyperplasia: Critical Comments on a Randomised Study." Urologia Journal 61, no. 3 (June 1994): 197–201. http://dx.doi.org/10.1177/039156039406100306.

Повний текст джерела

Анотація:

In an attempt to form a hypothesis (not yet verified) regarding the most active medical treatment in benign prostatic hyperplasia, a randomised study was carried out on three groups, evaluating a minimun of 4 months therapy. 52 patients received Finasteride (Group A), 43 received Alfuzosina (Group B) and 42 were treated with an association of Finasteride and Alfuzosina (Group C). There was a statistically significant variation in all the assessed urodynamic parameters, except for micturitional resistance, where group B showed more benefit than group C and group C more than group A. However, clinical evaluation was only able to positively judge the influence of the three therapy groups on the I-PSS improvement, among other things not correlated to the variation in obstruction parameters, which although showing definite improvement, mostly remained in the pathological range.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Metias, Youstina Mekhail, Emad Mohamed Hussien, Mervat Mohamed Hosny, and Magda Mohamed Ayad. "Development of Green Differential Pulse Voltammetric Strategy for the Determination of Alfuzosin Hydrochloride at Pencil Graphite and Modified Carbon Paste Electrodes." Acta Chimica Slovenica 69, no. 3 (September 26, 2022): 507–18. http://dx.doi.org/10.17344/acsi.2022.7348.

Повний текст джерела

Анотація:

A sensitive and inexpensive differential pulse voltammetric technique was applied to investigate the electrochemical behavior of alfuzosin hydrochloride at two different working electrodes: silica gel modified carbon paste and pencil graphite electrodes (PGE). The voltammetric conditions were optimized using cyclic voltammetry, showing an irreversible anodic peak in Britton-Robinson buffered medium (pH 6) at 0.86–0.90 V. The electrochemical responses were linearly correlated with alfuzosin concentrations (R2 > 0.999) in the ranges of 0.6–20 and 0.3–20 μM, exhibiting higher electrocatalytic activity at PGE with a low detection limit/ detectability of 0.099 μM. In addition, this study was a successful attempt for the drug determination in tablets and spiked urine samples with green profile evaluation, employing the National Environmental Methods Index, analytical Eco-Scale score, and Green Analytical Procedure Index.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Rangaiah, Rohit Garagadahalli, and Vilvapathy Senguttuvan Karthikeyan. "Role of alpha blockers and 7-days catheterization in enhancing the success of trial void in acute urinary retention due to benign prostatic hyperplasia: a double-blind randomized control trial." International Surgery Journal 5, no. 10 (September 25, 2018): 3256. http://dx.doi.org/10.18203/2349-2902.isj20184072.

Повний текст джерела

Анотація:

Background: Acute urinary retention (AUR) in patients with benign prostatic hyperplasia (BPH) is common. This study evaluated the efficacy of three alpha-blockers with urethral catheterization for 7 days in trial without catheter (TWOC).Methods: This was a prospective, randomized, double-blind, active-control study conducted between November 2013 and May 2016. Patients aged more than 50 years, presenting with first-time painful AUR due to BPH were enrolled in this study. Eligible patients were randomized (1:1:1) to one of the three treatment groups to receive tamsulosin 0.4 mg, alfuzosin 10 mg or silodosin 8 mg for one week. The primary outcome measure was successful TWOC at 7 days.Results: A total of 118 patients were included in the study (tamsulosin, n=40; alfuzosin, n=38; and silodosin, n=40). The baseline parameters were comparable between the three groups. A total of 84 (71.2%) patients had successful TWOC at the end of 7 days (tamsulosin, n=30 (75%); alfuzosin, n=32 (84%); and silodosin, n=22 (55%)) and was significantly (p=0.015) different between three groups. Higher age, larger volume at retention and higher prostate volume were significantly (p<0.05) associated with the failure of TWOC.Conclusions: Results from this study demonstrate that there is a definite role of 7-day catheterization with alpha blockers in improving the rates of success of TWOC in men presenting with AUR due to BPH. The success of TWOC is multifactorial.

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Titos-Arcos, José Carlos, Hacibe Hallal, Raúl J. Andrade, and Aurelio López Martín. "Lesión hepatocelular recurrente por alfuzosina." Gastroenterología y Hepatología 34, no. 2 (February 2011): 125–27. http://dx.doi.org/10.1016/j.gastrohep.2010.09.009.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Humayun, Fawad, Ghulam Mujtaba, Muhammad Seerwan, Ghazi Khan, Naseem Javed, and Muhammad Adnan. "EFFICACY OF ALFUZOSIN VERSUS CONTROL GROUP IN UPPER URETERIC STONE EXPULSION IN ADULT POPULATION OF LAHORE, PAKISTAN." Gomal Journal of Medical Sciences 19, no. 4 (January 18, 2022): 127–31. http://dx.doi.org/10.46903/gjms/19.04.904.

Повний текст джерела

Анотація:

Background: Urinary stone disease is one of the commonest urological diseases worldwide. The objective of this study was to compare the efficacy of alfuzosin versus control group in upper ureteric stone expulsion in adult population of district Lahore, Pakistan.Materials Methods: This trial was conducted in Department of Urology, Sheikh Zayed Hospital, Lahore, Pakistan form January 2017 to June 2017. All adult patients with upper ureteric stone size 5-10 mm were eligible. Those with multiple stones, having fever, severe pain, history of surgery in past two weeks and growth on urine culture or pyuria were excluded. Experimental and control groups each had 30 patients. Experimental group received Tab. alfuzosin 10 mg daily for four weeks and Tab. diclofenac sodium 50 mg SOS for acute pain. The control group received Tab. diclofenac sodium 50 mg SOS for acute pain. We followed all patients for four weeks for expulsion of ureteric stones by X-ray KUB or CT KUB. Sex, age and stone size were matching variables. Stone expulsion (yes, no) was research variable. We compared count of stone expulsion between two groups by using McNemar chi-square test at alpha 0.5 using GraphPad.Results: Out of 30 patients in experimental group, 23 (76.67%) were men and seven (23.33%) women and out of 30 in control group, 20 (66.67%) were men and 10 (33.33%) women, almost similar in both groups. Mean age in experimental group was 39.45±10.33 years and in control group it was 37.38±8.28 years, almost similar in both groups. Mean stone size was 7.45±1.47 (5-10) mm in the experimental and 7.28±1.68 (5-10) mm in control group, being comparable in both the groups. In experimental group, stone expulsion was achieved in 23 (76.67%) cases and not in seven (23.33%) cases and in control group, it was achieved in 16 (53.33%) cases and not in 14 (46.67%) cases. There was statistically no significant difference in efficacy of alfuzosin versus control group (p=.1213).Conclusion: Our study showed no difference in efficacy of alfuzosin versus control group for upper ureteric stone expulsion in adult population of district Lahore, Pakistan.

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Kahkashan, Iram, Shabnam Chawdhary, Vishal R. Tandon, and Rahul Gupta. "To compare the efficacy and safety of silodosin and dutasteride combination with alfuzosin and dutasteride combination in patients of benign prostatic hyperplasia: a randomized, open label study." International Journal of Basic & Clinical Pharmacology 8, no. 4 (March 23, 2019): 635. http://dx.doi.org/10.18203/2319-2003.ijbcp20191095.

Повний текст джерела

Анотація:

Background: BPH is a major cause of bothersome lower urinary tract symptoms (LUTS) and affects quality of life (QoL) which deteriorates if not taken care with the passage of time. The aim and objective of the study was to compare the efficacy and safety of combination of silodosin and dutasteride with the combination of alfuzosin and dutasteride in patients of BPH.Methods: A randomized, open label, intention to treat study was carried out on newly diagnosed patients of BPH. Patients were randomly divided into two groups and followed up to 12 weeks. Group 1 of patients received a combination of silodosin 8 mg and dutasteride 0.5 mg (SD) (n=20) while the patients of group 2 received combination of alfuzosin 10 mg and dutasteride 0.5 mg (AD) (n=20). Primary endpoint was measured by changes in the mean baseline International prostate symptom score (I-PSS) and uroflowmetry and secondary outcome with changes observed on ultrasonography.Results: IPSS and IPSS-QOL significantly improved in both the treatment groups (p <0.001) along with mean maximum flow rate (Qmax) and mean average flow rate (Qavg). Prostate volume and residual urine volume showed a significant improvement in both the treatment groups at 12 weeks. However, the intergroup differences in IPSS, uroflowmetry and USG parameters were not significant. Both treatments were well tolerated.Conclusions: The current study established that both the drug combinations i.e. silodosin and dutasteride (SD) and alfuzosin and dutasteride (AD) largely have a comparable effect on both the dynamic and static components of BPH. Further, both drug combinations appear to have a comparable safety profile.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Kim, Seok Yeon, Byung-Ho Kim, Seok Ho Dong, Hyo Jong Kim, Young Woon Chnag, Rin Chang, and Yoon Wha Kim. "Alfuzosin-induced Acute Liver Injury." Korean Journal of Hepatology 13, no. 3 (2007): 414. http://dx.doi.org/10.3350/kjhep.2007.13.3.414.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Chapple, ChristopherR. "Alfuzosin for benign prostatic hypertrophy." Lancet 338, no. 8760 (July 1991): 182. http://dx.doi.org/10.1016/0140-6736(91)90167-n.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Jardin, A., H. Bensadoun, M. C. Delauche-Cavallier, and P. Attali. "Alfuzosin for benign prostatic hypertrophy." Lancet 338, no. 8772 (October 1991): 947. http://dx.doi.org/10.1016/0140-6736(91)91814-b.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Ramarao, Ch Taraka, J. Vijaya Ratna, and R. B. Srinivasa. "DESIGN AND CHARACTERIZATION OF ALFUZOSIN HCL GASTRORETENTIVE FLOATING MATRIX TABLETS EMPLOYING HPMC K 100M." INDIAN DRUGS 55, no. 11 (November 28, 2018): 71–73. http://dx.doi.org/10.53879/id.55.11.10741.

Повний текст джерела

Анотація:

The present investigation involves developing gastro retentive drug delivery systems (GFDDS) of alfuzosin HCl using HPMCK100M a is the matrixing agent and floating enhancer. Sodium bicarbonate in the acidic environment reacts with the acid and produces carbon dioxide. The gastro retentive tablets can be formulated to increase the gastric residence time and thereby increase the oral bioavailability. From the drug release study, it was concluded that the AFTB4 formula of HPMC K 100 M matrix tablets gives the controlled release up to 12 hours by showing increased release with floating lag time 24 seconds. Non – Fickian diffusion was the drug release mechanism from the matrix tablets formulated employing HPMC K 100 M. The matrix tablets (AFTB4) formulated employing 40 % HPMC K 100 M are best suited to be used for gastro retentive dosage form of alfuzosin HCl. Finally, it can be concluded that good candidates for the preparation of gastro retentive dosage forms due its gastric stability, gastric absorption and better bioavailability.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!